6533b86ffe1ef96bd12ce57a

RESEARCH PRODUCT

A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis

Brigida FierroV. La BuaGiuseppe SalemiGiovanni SavettieriS. ConteAurelio PiazzaD. BuffaFilippo Brighina

subject

medicine.medical_specialtyExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosismedicine.medical_treatmentMagnetic resonance imagingGeneral Medicinemedicine.diseaselaw.inventionSurgeryTranscranial magnetic stimulationNeurologyRandomized controlled trialMethylprednisolonelawAnesthesiamedicineSilent periodNeurology (clinical)Evoked potentialbusinessmedicine.drug

description

Objective To investigate the efficacy of two different high doses of intravenous methylprednisolone (IVMP) during Multiple Sclerosis (MS) relapses. Background Transcranial Magnetic Stimulation (TMS) is the most sensitive neurophysiological ascertainment to quantify motor disability, to follow the recovery from an MS relapse, and to detect the response to treatment. Design and method Twenty-four clinically definite relapsing - remitting MS patients presenting a relapse were randomly assigned to a treatment for 5 days with IVMP 1 or 2 g/day. The response to treatment of each patient was evaluated through Expanded Disability Status Scale (EDSS), Medical Research Council (MRC) score, and TMS by means of motor evoked potential (MEP) parameters. Results Motor threshold (MT), central motor conduction time (CMCT) and MRC showed a higher improvement with the highest dose of IVMP. Silent period and EDSS improved with both treatments. Conclusion The dose of 2 g/day of IVMP is more effective in MS relapse.

yearjournalcountryeditionlanguage
2002-03-01Acta Neurologica Scandinavica
https://doi.org/10.1034/j.1600-0404.2002.1o369.x